0001104659-21-045097.txt : 20210401 0001104659-21-045097.hdr.sgml : 20210401 20210401060339 ACCESSION NUMBER: 0001104659-21-045097 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210401 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210401 DATE AS OF CHANGE: 20210401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp CENTRAL INDEX KEY: 0001082554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521984749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26301 FILM NUMBER: 21795895 BUSINESS ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 BUSINESS PHONE: 3016089292 MAIL ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 FORMER COMPANY: FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP DATE OF NAME CHANGE: 19990324 8-K 1 tm2111622d1_8k.htm FORM 8-K
0001082554 false 0001082554 2021-04-01 2021-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  April 1, 2021

 

United Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   000-26301   52-1984749
(State or Other   (Commission   (I.R.S. Employer
Jurisdiction of   File Number)   Identification Number)
Incorporation)        

 

1040 Spring Street    
Silver Spring, MD   20910
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (301) 608-9292

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.01 per share   UTHR   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company      ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ¨

 

 

 

 

 

 

Item 8.01.  Other Events.

 

On April 1, 2021, United Therapeutics Corporation issued a press release announcing U.S. Food and Drug Administration approval of Tyvaso® (treprostinil) Inhalation Solution indication for the treatment of pulmonary hypertension associated with interstitial lung disease to improve exercise ability. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

TYVASO is a registered trademark of United Therapeutics Corporation.

 

Item 9.01. Exhibits

 

 

(d)  Exhibits
     
Exhibit No.   Description of Exhibit
     
99.1   Press release dated April 1, 2021
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  UNITED THERAPEUTICS CORPORATION
     
     
Dated: April 1, 2021 By: /s/ Paul A. Mahon
  Name: Paul A. Mahon
  Title: General Counsel

 

3

 

 

 EX-99.1 2 tm2111622d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

For Immediate Release

 

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

 

First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need

 

FDA approval based on data from the INCREASE clinical trial

 

PH-ILD is the second FDA-approved indication for Tyvaso, which was initially approved for the treatment of pulmonary arterial hypertension

 

SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., April 1, 2021 – United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso® (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. This is the second FDA-approved indication for Tyvaso, which was first approved in July 2009 for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

 

“Adults living with both interstitial lung disease and pulmonary hypertension typically have a poor quality of life because of increased shortness of breath, poor exercise tolerance, and increased mortality. Until now, clinicians treating these patients did not have any approved treatment options,” said Aaron Waxman, M.D., Ph.D., Director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital and the chair of the INCREASE Study Steering Committee. “The regulatory approval of Tyvaso, an inhaled treatment, is exciting news both for patients with PH-ILD and the physicians who treat adults living with this serious, life-threatening disease. This will change the way we manage these patients.”

 

Interstitial lung disease (ILD) is a group of lung diseases in which marked scarring occurs within the lungs. It is often complicated by pulmonary hypertension (PH; high blood pressure in the lungs), which further symptoms and decreases survival. PH is estimated to affect at least 15% of patients with early-stage ILD (approximately 30,000 PH-ILD patients in the United States) and may affect up to 86% of patients with more severe ILD.

 

“The FDA approval of Tyvaso for patients with PH-ILD is a landmark treatment advancement for this vulnerable patient population,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “It also underscores our commitment to driving innovation in the field of pulmonary hypertension and expanding the number of patients who can achieve a clinical benefit from Tyvaso. We plan to tap into our experience and expanded infrastructure to bring this safe and effective inhaled therapy to the many patients living with PH-ILD in the United States.”

 

“With this approval representing such a breakthrough for PH-ILD patients, we’re treating this indication launch with a sense of urgency,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “We’ve already expanded our field-based teams by 40% to educate the ILD community on the benefits of Tyvaso and how to properly diagnose PH-ILD. We expect rapid uptake of Tyvaso in this indication and expect to double the number of patients on Tyvaso therapy by the end of 2022, barring any COVID-related delays.”

 

The FDA approval of the supplemental New Drug Application (sNDA) for Tyvaso for PH-ILD is supported by data from INCREASE, the largest and most comprehensive completed study of adult patients with PH-ILD. The multicenter, randomized, double-blind, placebo-controlled, 16-week, parallel-group study of 326 patients met its primary endpoint, demonstrating a significant improvement in six-minute walk distance (6MWD). Results, published in the New England Journal of Medicine, and discussed at a recent United Therapeutics investor meeting, also showed benefits across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and dose. Significant improvements were also observed in each of the secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at week 12, and change in trough 6MWD at week 15. Additional observations included placebo-corrected improvements in forced vital capacity (FVC) and significantly fewer exacerbations of underlying lung disease in patients receiving Tyvaso. Treatment with Tyvaso of up to 12 breaths per session, four times daily, in the INCREASE study was well tolerated and the safety profile was consistent with previous Tyvaso studies and known prostacyclin-related adverse events (see the Important Safety Information below under “About TYVASO® (treprostinil) Inhalation Solution”).

 

1

 

 

About PH-ILD

Interstitial lung disease (ILD) is a group of lung diseases that are characterized by marked scarring or fibrosis of the bronchioles and alveolar sacs within the lungs. Increased fibrotic tissue in ILD prevents oxygenation and free gas exchange between the pulmonary capillaries and alveolar sacs, and the condition can present with a wide range of symptoms, including shortness of breath with activity, labored breathing, and fatigue.

 

WHO Group 3 Pulmonary hypertension (PH) frequently complicates the course of patients with interstitial lung disease and is associated with worse functional status measured by exercise capacity, greater supplemental oxygen needs, decreased quality of life, and worse outcomes. PH is estimated to affect at least 15% of patients with early-stage ILD (approximately 30,000 PH-ILD patients in the United States) and may affect up to 86% of patients with more severe ILD.

 

About TYVASO® (treprostinil) Inhalation Solution

 

INDICATION

 

TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of:

 

·Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

 

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

 

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

 

·Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).

 

2

 

 

IMPORTANT SAFETY INFORMATION

 

WARNINGS AND PRECAUTIONS

·TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension.

 

·TYVASO inhibits platelet aggregation and increases the risk of bleeding.

 

·Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.

 

DRUG INTERACTIONS/SPECIFIC POPULATIONS

·The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.

 

·Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.

 

·Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.

 

·Safety and effectiveness in pediatric patients have not been established.

 

·Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH-ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.

 

ADVERSE REACTIONS

·Pulmonary Arterial Hypertension (WHO Group 1)

 

In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.

 

·Pulmonary Hypertension Associated with ILD (WHO Group 3)

 

In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions were similar to the experience in studies of PAH.

 

Please see Full Prescribing Information, the TD-100 and TD-300 TYVASO® Inhalation System Instructions for Use manuals, and other additional information at www.tyvaso.com or call 1-877-UNITHER (1-877-864-8437).

 

3

 

 

United Therapeutics: Enabling Inspiration

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.

 

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

 

Please visit unither.com to learn more.

 

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to the potential for the approval of Tyvaso in PH-ILD to change the way PH-ILD patients are treated, our expectation of a rapid uptake of Tyvaso in PH-ILD patients, and our expectation that we will double the number of patients on Tyvaso therapy by the end of 2022, our ability to create value and sustain our success in the long-term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 1, 2021, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

 

TYVASO is a registered trademark of United Therapeutics Corporation.

 

 

For Further Information Contact:

Dewey Steadman at (202) 919-4097

Email: ir@unither.com

 

# # #

 

4

 

 

 EX-101.SCH 3 uthr-20210401.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 uthr-20210401_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 uthr-20210401_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2111622d1_ex99-1img01.jpg GRAPHIC begin 644 tm2111622d1_ex99-1img01.jpg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end XML 7 tm2111622d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001082554 2021-04-01 2021-04-01 iso4217:USD shares iso4217:USD shares 0001082554 false 8-K 2021-04-01 United Therapeutics Corporation DE 000-26301 52-1984749 1040 Spring Street Silver Spring MD 20910 301 608-9292 false false false false Common Stock, par value $0.01 per share UTHR NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
Apr. 01, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 01, 2021
Entity File Number 000-26301
Entity Registrant Name United Therapeutics Corporation
Entity Central Index Key 0001082554
Entity Tax Identification Number 52-1984749
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1040 Spring Street
Entity Address, City or Town Silver Spring
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20910
City Area Code 301
Local Phone Number 608-9292
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol UTHR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://unither.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2111622d1_8k.htm tm2111622d1_ex99-1.htm uthr-20210401.xsd uthr-20210401_lab.xml uthr-20210401_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2111622d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2111622d1_8k.htm" ] }, "labelLink": { "local": [ "uthr-20210401_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "uthr-20210401_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "uthr-20210401.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uthr", "nsuri": "http://unither.com/20210401", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2111622d1_8k.htm", "contextRef": "From2021-04-01to2021-04-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://unither.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2111622d1_8k.htm", "contextRef": "From2021-04-01to2021-04-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-045097-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-045097-xbrl.zip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